STOCK TITAN
  1. Home
  2. News
  3. CATX

Perspective Therapeutics (CATX) Stock News

CATX NYSE

Welcome to our dedicated page for Perspective Therapeutics news (Ticker: CATX), a resource for investors and traders seeking the latest updates and insights on Perspective Therapeutics stock.

Perspective Therapeutics develops radiopharmaceutical candidates for cancer using proprietary Lead-212 (212Pb) technology and specialized targeting moieties. Its updates center on a theranostic approach that pairs targeted alpha therapy with complementary imaging diagnostics.

Recurring CATX news covers clinical and conference updates for VMT-α-NET in SSTR2-expressing neuroendocrine tumors, VMT01 for melanoma, and PSV359 for solid tumors, along with business results, financing activity, manufacturing infrastructure, 212Pb generator-enabled finishing facilities, and corporate presentations.

News

Perspective Announces Presentation of Positive Early Clinical Data for VMT-α-NET at the 36th Annual Congress of the European Association of Nuclear Medicine

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.95%
Tags
clinical trial
-
News

Perspective Therapeutics Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
none
-
News

Perspective Therapeutics to Present at the World Molecular Imaging Congress 2023

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
conferences
News

Perspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear Medicine

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
conferences clinical trial
-
News

Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
clinical trial
-
News

Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
earnings
News

Perspective Therapeutics and GT Medical Technologies Collaborate to Expand Access to Unique Cesium-131 Based Brain Cancer Treatment

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.68%
Tags
none
-
News

Perspective Therapeutics’ Cesium-131 Featured at the American Brachytherapy Society’s Annual Conference

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
-
News

Perspective Therapeutics Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
clinical trial
News

Perspective Therapeutics’ Cesium-131 to be Featured in Presentations at the 2023 American Brachytherapy Society’s Annual Meeting

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.37%
Tags
none

FAQ

What is the current stock price of Perspective Therapeutics (CATX)?

The current stock price of Perspective Therapeutics (CATX) is $2.95 as of June 12, 2026.

What is the market cap of Perspective Therapeutics (CATX)?

The market cap of Perspective Therapeutics (CATX) is approximately 338.7M.